New drugs and indications in 2013: little real progress but regulatory authorities take some positive steps.
2013 saw few therapeutic innovations that really benefitted patients; once again, marketing authorisations were too often granted despite inadequate clinical data. The French health authorities implemented a few measures designed to protect patients from dangerous drugs, including market withdrawals, restrictions on use, and delisting.